Back to Search
Start Over
COVID-19 and Avoiding Ibuprofen. How Good Is the Evidence?
- Source :
-
American journal of therapeutics [Am J Ther] 2020 Jul/Aug; Vol. 27 (4), pp. e400-e402. - Publication Year :
- 2020
-
Abstract
- Ibuprofen is an over-the-counter medication that is used widely for the treatment of pain and fever during COVID-19 pandemic. A concern was raised regarding the safety of ibuprofen use because of its role in increasing ACE2 levels within the Renin-Angiotensin-Aldosterone system. ACE2 is the coreceptor for the entry of SARS-CoV-2 into cells, and so, a potential increased risk of contracting COVID-19 disease and/or worsening of COVID-19 infection was feared with ibuprofen use. However, available data from limited studies show administration of recombinant ACE2 improves lung damage caused by respiratory viruses, suggesting ibuprofen use may be beneficial in COVID-19 disease. At this time, there is no supporting evidence to discourage the use of ibuprofen.
- Subjects :
- Angiotensin-Converting Enzyme 2
Angiotensin-Converting Enzyme Inhibitors therapeutic use
Animals
Anti-Inflammatory Agents, Non-Steroidal therapeutic use
Betacoronavirus
COVID-19
Coronavirus Infections drug therapy
Evidence-Based Medicine
Humans
Ibuprofen therapeutic use
Lung drug effects
Pandemics
Peptidyl-Dipeptidase A biosynthesis
Pneumonia, Viral drug therapy
Receptors, Virus drug effects
Renin-Angiotensin System drug effects
SARS-CoV-2
Anti-Inflammatory Agents, Non-Steroidal adverse effects
Coronavirus Infections complications
Ibuprofen adverse effects
Pneumonia, Viral complications
Subjects
Details
- Language :
- English
- ISSN :
- 1536-3686
- Volume :
- 27
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- American journal of therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 32366740
- Full Text :
- https://doi.org/10.1097/MJT.0000000000001196